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Catalytic Asymmetric Aldehyde Prenylation and Application in 
the Total Synthesis of (‒)-Rosiridol and (‒)-Bifurcadiol  
Yu-Long Zhang,a Zhen-Ni Zhao,a Jing-Jie Li,a Wang-Lai Li,a Subarna Jyoti Kalita,a Uwe 
Schneiderb and Yi-Yong Huanga,* 
Chiral phosphoric acid-catalyzed asymmetric aldehyde 
prenylation has been established using an a,a-dimethyl allyl 
boronic ester.  The transformation provides an expedient access 
to a wide array of aryl, heteroaryl, aryl-substituted alkenyl as well 
as primary and secondary aliphatic homoprenyl alcohols with 
excellent asymmetric induction.  The utility of this asymmetric 
catalysis strategy has been demonstrated through a short and 
efficient total synthesis of the two natural products (‒)-rosiridol 
and (‒)-bifurcadiol. 
 
Enantiomerically enriched homoprenyl alcohols are not only versatile 
building blocks,1 but also widely present as key motifs in 




Figure 1.  Selected natural products containing an enantioenriched 
homoprenyl alcohol motif. 
 
Indeed, inotodiol (I) displays significant anti-tumor activity, including 
human cervical cancer.3  Shikonin (II) exhibits anti-bacterial and anti-
tumor activities while its enantiomer (alkannin) has been used as anti-
oxidant, anti-tumor, and anti-thrombotic agents, and in wound 
healing.4  (–)-Rosiridol (III) and its glycosylated derivatives inhibit 
monoamine oxidase B (MAO B), which is involved in 
neurodegenerative diseases.5  (–)-Bifurcadiol (IV) displays anti-ulcer 
and anti-tumor activities.6  Furaquinocin D (V) shows a wide range of 
biological effects including anti-hypertensive activity, inhibition of 
platelet aggregation and coagulation.7  Sargachromanol C (VI) has 
been identified as a potential anti-cancer and anti-mutagenic agent as 
well as an inhibitor of Na+/K+ ATPase and isocitrate lyase.8  
In this context, the invention of efficient asymmetric catalysis 
methods to assemble enantiomerically enriched homoprenyl alcohols9 
and the corresponding natural products or potential drugs represents a 
significant task for synthetic organic chemists.10  To date, two types 
of synthetic strategies have been documented to achieve this goal; 
reduction (C–H bond formation) and C–C bond formation (Scheme 
1).  The first approach relies on the asymmetric reduction of prenyl 
ketones using a stoichiometric amount of a chirally modified B-
based11a–c or Al-based11d reductant; accordingly, the asymmetric total 
syntheses of shikonin (II),11a,b alkannin (ent-II),11a,b (–)-rosiridol 
(III),11c and (–)-bifurcadiol (IV)11d have been described (Scheme 1–
1).  The second approach relies on the use of a chiral reagent or 
catalyst in order to access enantioenriched homoprenyl alcohols via 
C–C bond formation.  Suzuki et al. reported the total synthesis of (–)-
furaquinocin D (V) from an enantioenriched terminal epoxide and an 
alkenyl stannane in the presence of stoichiometric amounts of BuLi 
and BF3•OEt2 (single example; Scheme 1–2).12  Here, the reaction 
proceeds via Sn–Li transmetalation followed by boron-mediated 
epoxide ring-opening with the in situ-generated alkenyl lithium 
species.  Loh et al. reported a TfOH-catalysed prenylation using 
aldehydes and an enantioenriched prenyl 1,5-diol (8 examples; 
Scheme 1–3a);13 after initial condensation, the chirality transfer 
proceeds via an oxonia-Cope rearrangement followed by hydrolysis 
to give the corresponding homoprenyl alcohols (87–98% ee).  Cozzi 
and Umani-Ronchi et al. reported a catalytic asymmetric Nozaki–
Hiyama reaction using benzaldehyde and prenyl chloride in the 
presence of an enantioenriched chromium complex and stoichiometric 
amounts of Mn(0) and Me3SiCl to afford the corresponding 
homoprenyl alcohol with 42% ee (single example; Scheme 1–3b);14  
While catalytic asymmetric prenylation across C=C double bonds 
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carbonyl electrophiles to access enantioenriched homoprenyl alcohols 
has remained elusive.16  Since the asymmetric g-regioselective allyl 
boration of aldehydes catalysed by an enantioenriched Brønsted acid 
provides a short and efficient access to homoallyl alcohols,17 we have 
anticipated the possibility of using an a,a-dimethyl allyl boronic 
ester18 to create an unprecedented catalytic entry to homoprenyl 
alcohols with high asymmetric induction (Scheme 1–3c).  
Accordingly, complex chiral molecules containing a homoprenyl 
alcohol motif could be concisely installed by asymmetric catalysis.  In 
this communication, we describe a simple, general, and highly regio- 
and enantioselective aldehyde prenylation controlled by an (R)-
BINOL-derived phosphoric acid catalyst, and applications to the total 




Scheme 1.  Access to enantioenriched homoprenyl alcohols: 
literature background and this work’s approach. 
 
In our initial prenylation model study, benzaldehyde (1a) was used 
with a,a-dimethyl allyl boronic ester 2 in toluene in the presence of 
4Å molecular sieves (Table 1).  In the absence of a catalyst, 
homoprenyl alcohol 3a (racemic) was formed at room temperature in 
82% yield (5 h; entry 1).  In order to suppress this background reaction 
in view of an intended asymmetric version, a chiral Brønsted acid 
catalysis strategy was applied at 0 oC.  In the presence of 10 mol% of 
(R)-BINOL-derived chiral phosphoric acid (R)-4a, product 3a was 
obtained in 86% yield with 73% ee (entry 2).  The catalytic use of 
other chiral phosphoric acids (R)-4b–d has proved less effective (26–
64% ee; entries 3–5).  Similarly, the reactions using (R)-4a in THF 
and DCM gave product 3a in only 60% ee and 48% ee, respectively 
(entries 6 and 7).  Next, we investigated the effect of the reaction 
temperature on the asymmetric induction (entries 8–12).  Gratifyingly, 
3a was formed with 95% ee at –20 oC (entry 8); the best result was 
obtained at –60 oC over 32 h (93% yield, 98% ee; entry 12).  A control 
experiment in the absence of 4Å molecular sieves resulted in the 
formation of 3a with only 76% ee (entry 13); this result suggests that 
traces of water display a detrimental effect on the asymmetric 
induction, likely by disturbing the H-bond donor ability of the chiral 
catalyst.  Finally, the effect of the catalyst loading was probed thereby 
confirming that 10 mol% was the appropriate amount for this 
transformation (entries 14 and 15).  The standard reaction conditions 
for the following studies refer to the optimised conditions displayed 
in entry 12 of Table 1: 2 (1.5 equiv), (R)-4a (10 mol%), 4Å MS, 
toluene, –60 oC. 
 




The optimal reaction conditions were applied to a wide variety of 
aldehydes to probe the versatility of our methods (Scheme 2).  
Initially, the effect of diverse substituents at the para, meta, and ortho 
positions of the aromatic ring was examined.  The use of aromatic 
aldehydes bearing para-located electron-donating, neutral, and 
electron-withdrawing groups gave the corresponding homoprenyl 
alcohols 3b–k with 94–98% ee.  Meta-located substituents (MeO, Br, 
CN) were also tolerated; the corresponding products 3l–n were 
formed with 95–97% ee.  The use of aromatic aldehydes with an 
ortho-located F atom and Me group gave homoprenyl alcohols 3o and 
3p with 90% ee and 96% ee, respectively.  The use of 6-
bromopiperonal (1q) under slightly modified conditions provided 
product 3q with 90% ee; the absolute configuration of (+)-3q was 
determined to be R based on an X-ray crystallographic analysis.19  By 
analogy, the absolute configuration of all other aromatic homoprenyl 
alcohols was also assigned to be R.  Product 3r, derived from 3,4-
dimethylbenzaldehyde, was produced with 99% ee.  Naphthalene- and 
thiophene-derived aldehydes were converted into the corresponding 
homoprenyl alcohols 3s–v with 96–99% ee.  In addition, aryl-
substituted alkenyl aldehydes 1w and 1x were used to give the 
corresponding products 3w and 3x with 93% ee and 98% ee, 
respectively.  Finally, challenging primary and secondary aliphatic 
aldehydes 1y–z and 1aa were used to provide homoprenyl alcohols 






(1) Asymmetric reduction of prenyl ketones (C–H bond formation; refs 11a–d)













































R = Ar, 1o alkyl
single example
(a) Use of an enantioenriched prenyl 1,5-diol in the presence of a Brønsted acid catalyst (ref 13)
(b) Use of prenyl chloride in the presence of a chiral Lewis acid catalyst (ref 14)



































(R)-4a: Ar = 2,4,6-(iPr)3-C6H2
(R)-4b: Ar = SiPh3
(R)-4c: Ar = 3,5-(tBu)2-4-OMe-C6H2















4a toluene –60 32 93 98
toluene –60
toluene







4a THF   0 12 89 60
  04a DCM 10 93 48








[a] Reaction conditions (unless otherwise specified): 1a (0.10 mmol), 2 (0.15 
mmol), (R)-4 (10 mol%), 4 Å MS (25 mg), solvent (0.3 mL).  [b] Isolated yield.  [c] 
The enantiomeric excess (ee) was determined by chiral HPLC analysis.  [d] In the 
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Next, we focused on applying this asymmetric catalysis method to 
the total synthesis of the natural products (–)-rosiridol (III) and (–)-
bifurcadiol (IV).  As mentioned before, the total synthesis of these 
compounds was achieved through a critical asymmetric reduction of 
the corresponding prenyl ketone using a stoichiometric amount of a 
chiral reductant.11c,d  Moreover, the construction of the prenyl ketone 
substrates required three steps: prenylation of aldehyde 8 (cf. Scheme 
3) or 13 (cf. Scheme 4); oxidation of the resulting alcohol to the 
corresponding ketone; asymmetric reduction.  Such approach is 
arguably more tedious and less sustainable than a direct catalytic 
asymmetric prenylation of 8 or 13.  With this in mind, we synthesised 
alkenyl aldehyde 8 (Scheme 3).  Distinct from the reported 
synthesis,11c we installed a trityl (Tr) protecting group on primary 
alcohol 5 in 96% yield.  The resulting ether 6 underwent standard 
allylic oxidation to form alcohol 7 in 40% yield.  Subsequent 
oxidation of allylic alcohol 7 using MnO2 gave substrate 8 in 85% 
yield.  The catalytic asymmetric prenylation of 8 using 2 was carried 
out under the optimised conditions to form homoprenyl alcohol 9 in 
89% yield with 99% ee (Scheme 3).  Finally, the removal of the 
protecting group gave (–)-rosiridol (III) in 85% yield.  Based on the 
reported S-configuration of III,11c the stereogenic centre in alcohol 9 
must be consequently also S-configured.  Therefore, the C–C bond 
formation between alkenyl aldehyde 8 and 2 (prenylation) must have 
occurred from the aldehyde’s Re-face; interestingly, this would be 
opposite to the case of aromatic aldehydes (Si-face attack; cf. Scheme 
2).  Compared with the reported stoichiometric methods,11 the present 
synthesis is shorter and the stereogenic centre was formed by 
asymmetric catalysis.  Encouraged by this success, a short total 
synthesis of (–)-bifurcadiol (IV) was also achieved in five similar 
steps starting from alcohol 10 (Scheme 4).11d  Here, the precursor to 
IV, homoprenyl alcohol 14, was formed under the optimised 
conditions in 93% yield with 99% ee (Scheme 4); the absolute 
configuration of the created stereogenic centre in 14 was determined 
as S by comparison with the earlier report on IV.11d  Thus, it turns out 
that the enantiofacial discrimination using alkenyl aldehydes is 
opposite to the one using aromatic aldehydes. 
 
     
 
Scheme 3.  Synthetic route to (–)-rosiridol (III). 
 
   
 
Scheme 4.  Synthetic route to (–)-bifurcadiol (IV).    
Conclusions 
In summary, we have established the first example of highly 
enantioselective general aldehyde prenylation16 controlled by a 
chiral phosphoric acid catalyst.  A broad range of 
enantioenriched aryl, heteroaryl, aryl-substituted alkenyl, as well 
as primary and secondary aliphatic homoprenyl alcohols have 
been constructed regioselectively in high yields with excellent 
asymmetric induction.  The synthetic pathways to the two natural 
products (–)-rosiridol and (–)-bifurcadiol were streamlined by 
virtue of this catalytic asymmetric prenylation method.  Further 
applications of the a,a-dimethyl allyl boronic ester in other 
asymmetric reactions will be reported in due course. 
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94% yield, 84% ee
[a] Reaction conditions (unless otherwise specified): 1 (0.10 mmol), 2 (0.15 mmol), (R)-4a (10 mol%), 
4Å MS (25 mg), solvent (0.3 mL); yield of isolated product; ee values were determined by chiral HPLC 
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